New CAR-T therapy tested for patients with aggressive blood cancers
NCT ID NCT07312630
Summary
This is an early safety study testing a new CAR-T cell therapy called LV009 for adults with certain blood cancers (like non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have come back or not responded to other treatments. The main goals are to find a safe dose and see how the body processes the modified immune cells. It is enrolling a small number of participants to carefully monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PersonGen.Anke Cellular Therapeutice Co., Ltd.
RECRUITINGHefei, Anhui, 230088, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.